Long term CIN3+ risk of HPV pos. women after triage with FAM19A4/miR124-2, methylation analysis.
Dick et al, Gynaecological oncology 2019 Jun 7, S0090-8258(19)31279-X.
FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.
Luttmer et al, Br JCancer. 2016;115(5):579–87.
Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman et al, Int J Cancer. 2019 Jan 1;144(1):160-168.
Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
Leeman et al, Gynecol Oncol. 2018 Nov;151(2):311-318.
Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study.
Floore et al., J Clin Lab Anal. 2019 Feb 13:e22854.
Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. De Strooper, et al. Int J Cancer, 2018 Apr 16. doi: 10.1002/ijc.31539.
Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. De Strooper et al. Gynecol Oncology, vol 141(2), pp341-347, 2016.
Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynaecologic outpatient population (COMETH study). Luttmer et al. International Journal of Cancer, vol 138(4), pp992-1002, 2015
Methylation Analysis of the FAM19A4 Gene in Cervical Scrapes Is Highly Efficient in Detecting Cervical Carcinomas and Advanced CIN2/3 Lesions. De Strooper et al. Cancer prevention research, vol 7(12), pp1251-1257, 2014
Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Steenbergen et al. Nat Rev Cancer. 2014, 14:395-405.
Clinical validation of the HPV-Risk Assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. Hesselink et al. J Clin Microbiol. 2014;52(3):890-896.
Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Hesselink et al. Int J Cancer. 2014;135:880-6.
Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Verhoef et al. Lancet Oncol. 2014;15:315-22.
CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Bierkens et al. Int J Cancer. 2013;133:1293-9.
Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. Snellenberg et al. BMC Cancer. 2012;12:551.
Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Hesselink et al. Clin Cancer Res. 2011;17:2459-65.
Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Overmeer et al. Int J Cancer. 2011;129:2218-25.
Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel. Polman et al, J Clin Microbiol. 2017 Dec;55(12):3544-3551.
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older. Meijer et al. J. Cancer. 2009 February 1; 124(3): 516-520
Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Luttmer et al Expert Rev Mol Diagn. 2016 Sep;16(9):961-74.